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Poly lactic-co-glycolic acid (PLGA) is one of the most widely used synthetic polymers for 
development of delivery systems for drugs and therapeutic biomolecules. Its properties and 
versatility make it a reference polymer in the manufacturing of nano and microparticles to 
encapsulate and deliver a wide variety of hydrophobic and hydrophilic molecules, including 
biomolecules such as proteins or nucleic acids that must be released in a controlled way [1]. 
Delivery of growth factors such as bone morphogenetic proteins, and specially BMP-2, is 
an attractive therapeutic strategy for bone tissue engineering. However, their administration is 
problematic due to their short biological half-lives, localized action and rapid clearance. 
Consequently, its clinical use requires high doses far exceeding its physiological concentration 
which implies possible side effects and high costs. These barriers might be overcome by 
developing new delivery systems which allow a better control of the release rate in order to achieve 
the desired concentrations in specific site and time [2]. 
With this aim, in this preliminary study we have synthesized PLGA particles with different 
diameters, from nano (200 nm) to micro scale (12.5 μm) via double emulsion procedure, in order to 
study the influence of size in the release profile of lysozyme, which has been selected as an 
appropriate model for BMP2. A physico-chemical characterization of the particles was done, 
followed by a complete study on the encapsulation efficiency, cumulative protein release and 
bioactivity of the released enzyme with and without co-encapsulated bovine serum albumin, a 
protective biomolecule that can prevent protein instability during emulsification process. 
Additionally, fluorescently labeled lysozyme was used to study the protein distribution and the 
influence of particle size on the in vitro cellular uptake.  
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(A) STEM/ (B) SEM micrographies of PLGA/poloxamer188 blend nanoparticles. 
